Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsDenver Health Step Therapy Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentDenver-Health-Medical-PlanPolicy H5608_001ST27_C

    Step Therapy Requirements

    Customize your policy alerts

    Sign up for Denver-Health-Medical-Plan Policy H5608_001ST27_C alerts

    Get alerted when Policy H5608_001ST27_C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs step therapy and related prior-claim requirements for selected drugs and insulin administration supplies under the Elevate Medicare Choice (HMO D-SNP) plan.

    Policy Summary
    PayerDenver-Health-Medical-Plan
    PolicyStep Therapy Requirements
    Policy CodePolicy H5608_001ST27_C
    Change TypeNo material change
    Effective DateJan 1, 202745d
    Next Review DateN/A
    Key ActionSubmit or identify the applicable prior pharmacy claim, prerequisite therapy trial, indication, and payment pathway information for the affected product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    120 daysCommon prerequisite claim lookback
    Step 2Coverage level for listed affected products
    Part B vs Part DAdministrative payment pathway addressed
    25 daysHigh-intensity statin trial

    Covered Products and Administrative Requirements

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Amantadine Extended-Release

    Covered at Step 2 when the prerequisite claim is present.

    Prior claim for amantadine HCl immediate-release within the past 120 days.

    Antiulcer Agents

    Covered at Step 2 when the prerequisite claim is present.

    ALL of the following

    • Step 2 products include esomeprazole magnesium delayed-release granules for suspension 10 mg, 20 mg, or 40 mg, and omeprazole 20 mg/sodium bicarbonate 1.1 gram capsules.
    • Prior claim for a generic Federal Legend formulary version of an oral lansoprazole capsule, esomeprazole magnesium capsule, rabeprazole, omeprazole, or pantoprazole within the past 120 days.

    Aripiprazole Film

    Covered at Step 2 when the prerequisite trial is documented.

    ALL of the following

    • Step 2 products include OPIPZA 2 mg, 5 mg, or 10 mg oral film.
    • Trial of generic aripiprazole tablets within the past 120 days.

    Aripiprazole ODT

    Covered at Step 2 when the prerequisite claim is present.

    ALL of the following

    • Step 2 products include aripiprazole 10 mg or 15 mg disintegrating tablets.
    • Prior claim for one formulary oral antipsychotic within the past 120 days: risperidone, clozapine tablet, olanzapine, immediate-release quetiapine fumarate, ziprasidone, aripiprazole (tablet, film, or solution), asenapine, paliperidone, or lurasidone.

    Asenapine Patch

    Covered at Step 2 when the required oral generic antipsychotic claims are present.

    ALL of the following

    • Step 2 products include SECUADO 3.8 mg/24 hour, 5.7 mg/24 hour, or 7.6 mg/24 hour transdermal patches.
    • Claims for 2 formulary oral generic antipsychotics: lurasidone, risperidone, clozapine tablet, olanzapine, immediate-release quetiapine fumarate, ziprasidone, aripiprazole, or other listed formulary oral generic antipsychotics.

    Part B Versus Part D Administrative Step

    A prior qualifying claim supports Part D payment; other indications require a formulary exception before the drug is approved.

    ALL of the following

    • To assist in a Part B versus Part D payment determination, a prior claim for a rheumatoid arthritis, psoriasis, or active polyarticular juvenile idiopathic arthritis drug must be seen within the past 120 days.

      A qualifying prior claim supports Part D payment.

    • For all other indications, the Part B versus Part D payment determination must be made through the formulary exception process prior to approval of the drug.

      Submit a formulary exception before approval.

    Clozapine and Versacloz

    Covered at Step 2 when the prerequisite claim is present.

    ALL of the following

    • Step 2 product: clozapine 200 mg disintegrating tablet (including the applicable clozapine/Versacloz Step 2 products).
    • Prior claim for one formulary oral antipsychotic within the past 120 days: risperidone, clozapine tablet, olanzapine, immediate-release quetiapine fumarate, ziprasidone, aripiprazole, asenapine, paliperidone, or lurasidone.

    Drizalma Sprinkle

    Covered at Step 2 when the prerequisite claim is present.

    ALL of the following

    • Step 2 products include DRIZALMA SPRINKLE 20 mg, 30 mg, 40 mg, or 60 mg delayed-release capsules.
    • Prior claim for a formulary generic duloxetine capsule within the past 120 days.

    Enalapril Oral Solution

    Covered at Step 2 when the prerequisite claim is present.

    Prior claim for generic enalapril oral tablets within the past 120 days.

    Eslicarbazepine

    Covered at Step 2 when the prerequisite claims are present.

    ALL of the following

    • Step 2 products include eslicarbazepine 200 mg, 400 mg, 600 mg, or 800 mg tablets.
    • Prior claims for 2 generic anticonvulsant agents within the past 365 days: carbamazepine, divalproex sodium, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, valproic acid, zonisamide, or lacosamide.

    Estradiol-Femring

    Covered at Step 2 when the prerequisite claims are present.

    ALL of the following

    • Step 2 products include FEMRING 0.05 mg/24 hour or 0.1 mg/24 hour vaginal systems.
    • Prior claims for 2 of the following within the last 365 days: Premarin cream, estradiol cream, or estradiol vaginal tablets.

    High-Intensity Lipid-Lowering Products

    Covered at Step 2 when the applicable prerequisite therapy is documented.

    ONE of

    • Prior claim for generic fenofibrate within the last 120 days.
    • Prior 25-day trial within the past 120 days of a generic high-intensity statin formulary version: atorvastatin 40 mg or 80 mg, or rosuvastatin 20 mg or 40 mg.

      Otherwise, a step exception request is required.

    Iloperidone

    Covered at Step 2 when the prerequisite claims are present.

    Claim for 2 formulary oral generic antipsychotics within the past 365 days: lurasidone, risperidone, clozapine tablet, olanzapine, immediate-release quetiapine fumarate, ziprasidone, aripiprazole, asenapine, or paliperidone.

    Initial Approval Requirements

    Amantadine ER Initial Therapy

    Initial approval at Step 2 requires the following prerequisite.

    Prior immediate-release amantadine claim: Prior claim for amantadine hydrochloride immediate-release.within the past 120 days

    Katerzia Initial Therapy

    Initial approval at Step 2 requires the following prerequisite.

    Prior amlodipine tablet claim: Prior claim for amlodipine tablets.within the past 120 days

    Prerequisite Therapy and Payment Steps

    StepAffected productsRequired prerequisiteTime frame
    1
    OSMOLEX ER extended-release tablets
    Prior claim for immediate-release amantadine hydrochloride
    Within the past 120 days
    StepAffected productRequired prerequisiteTime frame
    1
    Katerzia 1 mg/mL oral suspension
    Prior claim for amlodipine tablets
    Within the past 120 days
    StepAffected productsRequired prerequisiteTime frame
    1
    Listed antiulcer products, including esomeprazole magnesium delayed-release granules and omeprazole 20 mg-sodium bicarbonate capsules
    Prior claim for a generic federal legend formulary oral proton-pump inhibitor: lansoprazole, esomeprazole, rabeprazole, omeprazole, or pantoprazole
    Within the past 120 days
    StepAffected productRequired prerequisiteTime frame
    1
    Opipza 2 mg, 5 mg, or 10 mg oral film
    Trial of generic aripiprazole tablets
    Within the past 120 days
    StepAffected productRequired prerequisiteTime frame
    1
    Aripiprazole 10 mg or 15 mg orally disintegrating tablets
    Prior claim for one formulary oral antipsychotic: risperidone, clozapine tablet, olanzapine, immediate-release quetiapine fumarate, ziprasidone, aripiprazole, asenapine, paliperidone, or lurasidone
    Within the past 120 days
    StepAffected productRequired prerequisiteTime frame
    1
    Secuado 3.8, 5.7, or 7.6 mg/24 hour transdermal patch
    Claims for two formulary oral generic antipsychotics, including lurasidone, risperidone, clozapine tablet, olanzapine, immediate-release quetiapine fumarate, ziprasidone, or aripiprazole
    Two claims required; the document does not specify a lookback period in this criterion
    StepPayment pathwayRequired prerequisiteTime frame
    1
    Part D payment for qualifying indications; other indications require Part B versus Part D determination
    Prior claim for a qualifying drug for rheumatoid arthritis, psoriasis, or active polyarticular juvenile idiopathic arthritis; other indications require the formulary exception process before approval
    Within the past 120 days for the qualifying claim
    StepAffected productsRequired prerequisiteTime frame
    1
    Clozapine 12.5 mg, 25 mg, 150 mg, or 200 mg disintegrating tablets; Versacloz 50 mg/mL oral suspension
    Prior claim for one formulary oral antipsychotic: risperidone, clozapine tablet, olanzapine, immediate-release quetiapine fumarate, ziprasidone, aripiprazole, asenapine, paliperidone, or lurasidone
    Within the past 120 days
    StepAffected productRequired prerequisiteTime frame
    1
    Drizalma Sprinkle delayed-release capsules
    Prior claim for formulary generic duloxetine capsule
    Within the past 120 days
    StepAffected productRequired prerequisiteTime frame
    1
    Enalapril maleate 1 mg/mL oral solution
    Prior claim for generic enalapril oral tablets
    Within the past 120 days
    StepAffected productRequired prerequisiteTime frame
    1
    Eslicarbazepine 200 mg, 400 mg, 600 mg, or 800 mg tablets
    Prior claims for two generic anticonvulsant agents: carbamazepine, divalproex sodium, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, valproic acid, zonisamide, or lacosamide
    Within the past 365 days
    StepAffected productRequired prerequisiteTime frame
    1
    Femring 0.05 mg/24 hour or 0.1 mg/24 hour vaginal product
    Prior claims for two of the following: Premarin cream, estradiol cream, or estradiol vaginal tablets
    Within the past 365 days
    StepAffected productRequired prerequisiteTime frame
    1
    Omega-3 acid ethyl esters 1 gram capsules
    Prior claim for generic fenofibrate
    Within the past 120 days
    StepAffected productsRequired prerequisiteTime frame
    1
    Nexletol, Nexlizet, Repatha Pushtronex, Repatha SureClick, or Repatha syringe
    25-day trial of formulary high-intensity atorvastatin 40 mg or 80 mg, or rosuvastatin 20 mg or 40 mg
    Trial within the past 120 days; otherwise, a step exception request is required
    StepAffected productsRequired prerequisiteTime frame
    1
    Fanapt iloperidone tablets and titration packs
    Claims for two formulary oral generic antipsychotics: lurasidone, risperidone, clozapine tablet, olanzapine, immediate-release quetiapine fumarate, ziprasidone, aripiprazole, asenapine, or paliperidone
    Within the past 365 days
    StepAffected productsRequirementPayment determination
    2
    Listed insulin supplies, including pen needles, syringes, alcohol pads, and related supplies
    Use of a product listed under Step 2 of the insulin supply payment determination
    Insulin supply payment determination

    Documentation, Claims History, and Approval Risks

    Step Therapy

    Amantadine Extended-Release Step Therapy

    Before requesting coverage for amantadine extended-release products, submit documentation of a prior claim for immediate-release amantadine hydrochloride within the past 120 days. Without the qualifying claim, the request may be blocked or denied.

    • Affected Step 2 products: OSMOLEX ER 129 mg extended-release tablet; OSMOLEX ER 193 mg extended-release tablet; OSMOLEX ER 322 mg/day (129 mg and 193 mg) extended-release tablet.
    Step Therapy

    Amlodipine Tablet Prerequisite

    Before requesting Katerzia, submit documentation of a prior claim for amlodipine tablets within the past 120 days. A missing qualifying tablet claim may prevent approval.

    • Affected product: KATERZIA 1 mg/mL oral suspension.
    Step Therapy

    Antiulcer Prerequisite Therapy

    Step 2 antiulcer products require a prior claim for a generic federal-legend formulary oral proton-pump inhibitor within the past 120 days.

    • Qualifying therapies include generic formulary lansoprazole capsules, esomeprazole magnesium capsules, rabeprazole, omeprazole, or pantoprazole.
    • Affected products: esomeprazole magnesium delayed-release granules for suspension 10 mg, 20 mg, and 40 mg; omeprazole 20 mg-sodium bicarbonate 1.1 gram capsule.
    Step Therapy

    Aripiprazole Film Step Therapy

    A trial of generic aripiprazole tablets within the past 120 days is required before approval of the listed aripiprazole oral film products.

    • Affected products: OPIPZA 2 mg, 5 mg, and 10 mg oral film.

    Unsupported block type: step_therapy

    Step Therapy

    Asenapine Patch Step Therapy

    Secuado requires claims for two formulary oral generic antipsychotics before approval. Verify the claims history and document the qualifying therapies.

    • Qualifying therapies include lurasidone, risperidone, clozapine tablet, olanzapine, immediate-release quetiapine fumarate, ziprasidone, aripiprazole, and other listed formulary oral generic antipsychotics.
    • Affected products: SECUADO 3.8 mg/24 hour, 5.7 mg/24 hour, and 7.6 mg/24 hour transdermal patches.
    Documentation Required

    Part B Versus Part D Documentation

    For the listed products, document the indication and review the member’s claims history to support the Part B versus Part D payment determination. A prior claim for a qualifying indication drug within the past 120 days supports Part D payment.

    • Qualifying indications are rheumatoid arthritis, psoriasis, or active polyarticular juvenile idiopathic arthritis.
    • For all other indications, obtain the Part B versus Part D determination through the formulary exception process before approval.
    • Affected products include cyclophosphamide capsules/tablets, JYLAMVO, methotrexate sodium tablets, and XATMEP.
    Step Therapy

    Clozapine and Versacloz Prerequisite

    Before requesting clozapine disintegrating tablets or Versacloz, submit a prior claim for one formulary oral antipsychotic within the past 120 days.

    • Qualifying therapies include risperidone, clozapine tablet, olanzapine, immediate-release quetiapine fumarate, ziprasidone, aripiprazole, asenapine, paliperidone, or lurasidone.
    • Affected products include clozapine 12.5 mg, 25 mg, 150 mg, and 200 mg disintegrating tablets and VERSACLOZ 50 mg/mL oral suspension.
    Step Therapy

    Drizalma Sprinkle Step Therapy

    Drizalma Sprinkle requires a prior claim for formulary generic duloxetine capsules within the past 120 days.

    • Affected products: DRIZALMA SPRINKLE 20 mg, 30 mg, 40 mg, and 60 mg delayed-release capsules.
    Step Therapy

    Enalapril Oral Solution Prerequisite

    Before requesting enalapril oral solution, submit documentation of a prior claim for generic enalapril oral tablets within the past 120 days.

    • Affected product: enalapril maleate 1 mg/mL oral solution.
    Step Therapy

    Eslicarbazepine Prerequisite

    Eslicarbazepine requires claims for two generic anticonvulsant agents within the past 365 days.

    • Qualifying agents include carbamazepine, divalproex sodium, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, valproic acid, zonisamide, or lacosamide.
    • Affected strengths: eslicarbazepine 200 mg, 400 mg, 600 mg, and 800 mg tablets.
    Step Therapy

    Femring Step Therapy

    Femring requires prior claims for two specified vaginal estrogen products within the past 365 days.

    • Qualifying products: Premarin cream, estradiol cream, or estradiol vaginal tablets.
    • Affected products: FEMRING 0.05 mg/24 hr and 0.1 mg/24 hr vaginal rings.
    Step Therapy

    Omega-3 Acid Ethyl Esters Prerequisite

    Before requesting omega-3 acid ethyl esters, submit a prior claim for generic fenofibrate within the past 120 days.

    • Affected product: omega-3 acid ethyl esters 1 gram capsule.
    Step Therapy

    High-Intensity Statin Trial

    The listed lipid-lowering products require a prior 25-day trial of a generic formulary high-intensity statin within the past 120 days. If the trial requirement is not met, submit a step exception request as applicable.

    • Qualifying statins: atorvastatin 40 mg or 80 mg, or rosuvastatin 20 mg or 40 mg.
    • Affected products: NEXLETOL 180 mg tablet; NEXLIZET 180 mg-10 mg tablet; REPATHA PUSHTRONEX 420 mg/3.5 mL wearable injector; REPATHA SURECLICK 140 mg/mL pen; REPATHA SYRINGE 140 mg/mL syringe.
    Step Therapy

    Iloperidone Prior Antipsychotic Claims

    Fanapt products require claims for two formulary oral generic antipsychotics within the past 365 days. Verify and document both qualifying claims before submitting the request.

    • Qualifying therapies include lurasidone, risperidone, clozapine tablet, olanzapine, immediate-release quetiapine fumarate, ziprasidone, aripiprazole, asenapine, or paliperidone.
    • Affected products include Fanapt 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg tablets and titration packs A, B, and C.
    Billing Rule

    Step 2 Insulin Supply Products

    The insulin supply payment determination applies to the listed Step 2 insulin supply products. Identify the exact product and submit it under the applicable payment pathway.

    • Products include listed Unifine Pentips and Unifine Pentips Plus needles, Advocate pen needles, Advocate syringes, alcohol pads/prep pads/swabs/wipes, Aqinject pen needles, and Assure insulin needles and syringes.
    Documentation Required

    Prerequisite Therapy and Payment Documentation

    Before submitting a Step 2 request, verify the applicable prior claim or trial, the required lookback period, and any indication or payment-pathway documentation. Missing prerequisite history or an unresolved Part B versus Part D determination creates approval risk.

    • Applicable requirements include immediate-release amantadine, amlodipine tablets, generic oral proton-pump inhibitor therapy, generic aripiprazole tablets, formulary oral antipsychotics, or two qualifying antipsychotic claims.
    • Document qualifying indications and payment pathway for the Part B versus Part D administrative step.
    Note

    Criteria Pending CMS Review

    Anti-inflammatory agents gastrointestinal criteria remain pending CMS review. Do not represent this criterion as finalized; monitor for updated requirements before making an approval determination.

    • Affected category: ANTI-INFLAMMATORY AGENTS - GI.
    Denial Risk

    Approval and Denial Risk

    Requests may be denied or blocked when the required prerequisite claim, trial, or payment determination is absent or outside the applicable lookback period. Confirm claims history before submission, particularly for amantadine, amlodipine, antiulcer therapy, aripiprazole, and antipsychotic prerequisites.

    • Amantadine and amlodipine prerequisites generally require a claim within 120 days.
    • Other requirements use 120-day or 365-day lookback periods, or a specified 25-day statin trial.

    Policy Scope

    This section addresses insulin administration supplies and related skin or wound-care items. Affected products include insulin syringes, pen needles, safety syringes and safety pen needles, alcohol preparation pads or swabs, gauze bandages, and gauze sponges. The listed supplies are identified as Step 2 products, and payment determination is supported by a prior claim for an injectable insulin within the past 120 days.

    Policy Summary
    PayerDenver-Health-Medical-Plan
    PolicyStep Therapy Requirements
    Policy CodePolicy H5608_001ST27_C
    Change TypeNo material change
    Effective DateJan 1, 202745d
    Next Review DateN/A
    Key ActionSubmit or identify the applicable prior pharmacy claim, prerequisite therapy trial, indication, and payment pathway information for the affected product.
    SourceLink
    On This Page
    Covered Products and Administrative RequirementsInitial Approval RequirementsPrerequisite Therapy and Payment StepsDocumentation, Claims History, and Approval RisksPolicy Scope